Briefing
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction.
A whole-genome tumor-informed assay tracking 1,800 variants was applied to 2,994 plasma samples from 431 people with non-small cell lung cancer in TRACERx, and detection below 80 parts per million was prognostic before and after surgery.
- Design: Evidence level 2
- Assay: NeXT Personal